clinical trial · NCT07680946

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

$TGTX →·phase2·recruiting·n = 60

SchizophreniaUblituximab

brief summary

The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by positive and negative syndrome scale (PANSS) total score in participants with schizophrenia.

started

Jul 3, 2026

primary completion

Dec 1, 2028

completion

Mar 1, 2029

last updated

Jul 21, 2026

official title

Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol